Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INCA32459 |
| Synonyms | |
| Therapy Description |
INCA32459 is a bispecific antibody that targets both PD-1 (PDCD1) and LAG3, potentially leading to increased antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INCA32459 | INCA 32459|INCA-32459 | LAG3 Antibody 19 PD-L1/PD-1 antibody 132 | INCA32459 is a bispecific antibody that targets both PD-1 (PDCD1) and LAG3, potentially leading to increased antitumor immune response and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05577182 | Phase I | INCA32459 | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | Completed | USA | ITA | ESP | BEL | 0 |